A Pediatric Covariate Function for CYP3A-Mediated Midazolam Clearance Can Scale Clearance of Selected CYP3A Substrates in Children

類似資料

• Characterization of Intestinal and Hepatic CYP3A-Mediated Metabolism of Midazolam in Children Using a Physiological Population Pharmacokinetic Modelling Approach
  著者:: Brussee, Janneke M., 等
  出版事項: (2018)
• First‐Pass CYP3A‐Mediated Metabolism of Midazolam in the Gut Wall and Liver in Preterm Neonates
  著者:: Brussee, Janneke M., 等
  出版事項: (2018)
• Allometric Scaling of Clearance in Paediatric Patients: When Does the Magic of 0.75 Fade?
  著者:: Calvier, Elisa A. M., 等
  出版事項: (2016)
• Predicting CYP3A‐mediated midazolam metabolism in critically ill neonates, infants, children and adults with inflammation and organ failure
  著者:: Brussee, Janneke M., 等
  出版事項: (2017)
• Semiphysiologically based pharmacokinetic model for midazolam and CYP3A mediated metabolite 1‐OH‐midazolam in morbidly obese and weight loss surgery patients
  著者:: Brill, MJE, 等
  出版事項: (2015)